Sinovac: This is one is odd. According to Mohammed’s et al., (2022) study in Brazil where they’ve battled against Gamma variant of COVID, they found that 1 dose (49.6%) was more effective than 2 doses (36.8%) when they tested people after 14 or more days since the vaccine. Even stranger, they found that people who were vaccinated with Sinovac were much more likely to get COVID than someone that was unvaccinated (Mohammed et al., 2022).
Sinopharm: This vaccine also known as CoronaVac, has a reported efficiency of 79.34% (Siddique et al., 2021). This efficiency (a vaccines’ ability to produce the intended result) was found through Phase 3 clinical trials (the well respected kind of studies) done in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) (Siddique et al., 2021). But there are reports that Sinopharm, like Sinovac, the other inactivated vaccine, is not very effective against Omicron (Hart et al., 2022). Plus, studies that are in the process of being peer reviewed, have shown that the Sinopharm boosters are up to 8 times less effective against omicron than the AstraZeneca and Pfizer/BioNTech boosters (Hart et al., 2022). So it’s unsurprising that many countries that used Sinopharm initially are switching over to Pfizer/BioNTech, Moderna and AstraZeneca boosters (Hart et al., 2022).
Bharat Biotech: Also known as Covaxin has shown a clinical efficacy of 81% (Thiagarajan, 2021). This is extremely promising due to the low cost of this vaccine st R56,18 per person vs. the R512,24 per-person price tag of Pfizer (Thiagarajan, 2021). Covaxin also doesn’t need to be stored at sub-zero temperatures, so it can be safely stored at fridge temperatures – something that would be great for a lot of developing countries (Thiagarajan, 2021). But as stated by Talukder et al., (2022) there is currently no information on what Covaxin’s efficacy will be against omicron. Plus because it’s so new more research is needed on its safety and long term COVID-19 protection (Talukder et al., 2022).
Shifa Pharmed: This vaccine looks promising as it is an Omicron based vaccine which has shown good neutralising antibodies in the animal trial (Abdoli et al., 2022). But there’s still no conclusive evidence of how it will preform in the real world in human patients as it is still in phase one of clinical trials (Basiri et al., 2022).
Chinese Academy of Medical Sciences vaccine: Also known as imbcams or Covidful. There is currently no official efficiency for this vaccine as it currently in phase 3 of its clinical trials, but it is being tested in Brazil, Malaysia, the United Arab Emirates, and China. China has also approved the use of this vaccine for emergencies (Kantarcioglu et al., 2021).